Faeth Therapeutics, Inc. 8K

Faeth Therapeutics reported Q2 2026 results and announced strengthened capitalization, clinical progress with PIKTOR, a name and ticker change to FTH, and significant leadership and board changes following its combination with Sensei Biotherapeutics.

On August 4, 2026, Faeth Therapeutics, Inc. (Nasdaq: FTH) reported its financial results for the quarter ended June 30, 2026, and provided operational updates, including progress on its PIKTOR clinical programs, corporate rebranding, governance changes, and capital structure actions. The company highlighted that topline results from its Phase 2 PIK-201 trial in endometrial cancer remain on track for year-end 2026 and that the first patient was dosed in April in its Phase 1b/2 PIK-101 trial in HR+/HER2- advanced breast cancer, with initial safety and efficacy data expected in 2027. Faeth also disclosed that its combination with Sensei Biotherapeutics and a concurrent $200 million PIPE financing significantly strengthened its balance sheet, increasing cash, cash equivalents and marketable securities to $186.4 million as of June 30, 2026, while R&D and G&A expenses rose meaningfully year over year as the company scaled its PIKTOR development and public-company infrastructure. In June 2026, stockholders approved the conversion of Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement into common stock, the company changed its name to Faeth Therapeutics, Inc. and its common stock began trading under the ticker “FTH,” and governance changes were implemented with co-founder Anand Parikh becoming Chairman, President and CEO, Brian Stephenson, Ph.D., CFA, becoming CFO, and former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry joining the board.

Filing Facts

CIK

1829802

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-331563

Alert Tier

6